Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.32 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22345561 | 0.92 | CYP3A4 (0.31) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL1726219 | 0.91 | FDPS (0.35) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL29120197 | 0.78 | — | — | |
| SCHEMBL30827414 | 0.74 | CYP3A4 (0.33) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL9161298 | 0.74 | CYP3A4 (0.33) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL10879761 | 0.74 | ALDH1A1 (0.37) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL31555688 | 0.72 | CYP3A4 (0.32) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL29240387 | 0.72 | CYP3A4 (0.32) | CYP3A4ALDH1A1ADRB2ADRB1ADRB3 | |
| SCHEMBL29120183 | 0.71 | CHRM1 (0.31) | — | |
| SCHEMBL17860877 | 0.71 | ALDH1A1 (0.43) | CYP3A4ALDH1A1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | CLARIANT FINANCE (BVI) LIMITED (VG) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245386-A1 | Method for the Production of Mixed-Substituted Dialkylphosphinic Acids, Esters, and Salts, and Use Thereof | HAO2, ACSL3, SCO2 | CYP3A4 2114/4885ALDH1A1 3067/4885ADRB2 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.